Opko Health, Inc.
- Country
- 🇨🇱Chile
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 3.9K
- Market Cap
- -
- Website
- http://www.opko.com
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 338
- Registration Number
- NCT00499590
- Locations
- 🇺🇸
Retina Institute of California (site 207), Pasadena, California, United States
🇺🇸Miramar Eye Specialists Medical Group (site 245), Ventura, California, United States
🇺🇸Florida Eye Microsurgical Institute, Inc. (site 217), Boynton Beach, Florida, United States
Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis
- Conditions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT00384098
- Locations
- 🇺🇸
Radiant Research Inc., Anderson, South Carolina, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸New York University Medical Center, New York, New York, United States
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2008-07-25
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00306904
- Locations
- 🇺🇸
Retina Associates of Cleveland, Beechwood, Ohio, United States
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT00259753
- Locations
- 🇺🇸
Associated Retinal Consultants, P.C., Royal Oak, Michigan, United States
🇺🇸Retina-Vitreous Consultants, Livingston, New Jersey, United States
🇺🇸Vitreoretinal Consultants Houston TX, Houston, Texas, United States
A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1
- Conditions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00239187
- Locations
- 🇺🇸
Clinical Research of West Florida, Clearwater, Florida, United States
🇺🇸Diabetes and Glandular Disease Research Associates, San Antonio, Texas, United States
🇺🇸Profil Institute for Clinical Research Inc., Chula Vista, California, United States
A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1
- Conditions
- First Posted Date
- 2005-10-14
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00239148
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Diablo Clinical Research, Walnut Creek, California, United States
🇺🇸Diabetes - Endocrinology Center of West New York, Buffalo, New York, United States
Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin
- Conditions
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2019-10-18
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT00230854
- Locations
- 🇨🇦
L.H.S.C. University Campus, London, Ontario, Canada
🇨🇦Ottawa Hospital, Ottawa, Ontario, Canada